PolyPeptide Group AG
ISIN: CH1110760852 | Ticker: PPGN | LEI: 5067007JCKTPOX4G9758
Country: Switzerland
PolyPeptide Group is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with around 1,100 employees at the end of 2021, its diversity brings breadth, depth of knowledge and experience to the group.
PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing.
Worldwide
Headcount1,100
HeadquartersDammstrasse 19, 6300 Zug – Switzerland
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 26.04.22 | None | Non-Executive member | Buy | CHF 90,000.00 |
| 26.04.22 | None | Non-Executive member | Buy | CHF 70,000.00 |
| 26.04.22 | None | Non-Executive member | Buy | CHF 50,000.00 |
| 26.04.22 | None | Non-Executive member | Buy | CHF 45,000.00 |
CH1110760852
LEI5067007JCKTPOX4G9758
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.